FDA ApprovedUnited States
New Infusion Treatment for Thyroid Eye Disease
Lumvoa (veligrotug-vvze) for thyroid eye disease (active and chronic)
The FDA labelled an intravenous IGF-1R monoclonal antibody for thyroid eye disease regardless of disease activity or duration on 26 June 2026. The labelled…
Lumvoa (veligrotug) is an infusion for thyroid eye disease, whether the disease is active or long-standing.